Cellectis Buchwert je Aktie
Was ist das Buchwert je Aktie von Cellectis?
Buchwert je Aktie von Cellectis ist 4.36
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Cellectis
Was macht Cellectis?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Unternehmen mit buchwert je aktie ähnlich Cellectis
- Morses Club PLC hat Buchwert je Aktie von 4.35
- Nokian Renkaat Oyj hat Buchwert je Aktie von 4.36
- Tandy Leather Factory hat Buchwert je Aktie von 4.36
- Metalla Royalty & Streaming hat Buchwert je Aktie von 4.36
- Las Vegas Sands Corp hat Buchwert je Aktie von 4.36
- WPP Plc hat Buchwert je Aktie von 4.36
- Cellectis hat Buchwert je Aktie von 4.36
- Jacques Bogart SA hat Buchwert je Aktie von 4.36
- Bowl America hat Buchwert je Aktie von 4.36
- Insignia Systems hat Buchwert je Aktie von 4.36
- Crown Crafts hat Buchwert je Aktie von 4.36
- Co-Diagnostics hat Buchwert je Aktie von 4.37
- ASE Technology Co.Ltd hat Buchwert je Aktie von 4.37